published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsAbd-Elsalam, 2020 1.21 [0.36; 4.12] Chen, 2020 0.56 [0.01; 30.20] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] HYCOVID, 2020 0.54 [0.21; 1.40] NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78] ORCHID, 2020 1.07 [0.54; 2.11] RECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] TEACH, 2020 1.07 [0.34; 3.37] 1.10[0.99; 1.22]Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, HYCOVID, 2020, NO COVID-19 (Lyngbakken), 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020100%8,065moderatelow deaths (time to event analysis only)detailed resultsRECOVERY, 2020 1.09 [0.97; 1.23] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] 1.10[0.99; 1.23]RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202020%6,569moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.92 [0.61; 1.38] TEACH, 2020 1.80 [0.62; 5.21] 1.07[0.62; 1.85]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, TEACH, 2020225%458moderatenot evaluable clinical improvementdetailed resultsORCHID, 2020 1.02 [0.73; 1.42] 1.02[0.73; 1.42]ORCHID, 202010%479lownot evaluable clinical improvement (14-day)detailed resultsChen, 2020 0.56 [0.13; 2.48] 0.56[0.13; 2.48]Chen, 202010%33moderatenot evaluable death or ventilationdetailed resultsHYCOVID, 2020 1.12 [0.45; 2.79] RECOVERY, 2020 1.14 [1.03; 1.27] SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42] 1.14[1.03; 1.25]HYCOVID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 202030%6,023moderatenot evaluable PCR-negative conversiondetailed resultsHC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] 0.46[0.04; 5.75]HC-nCoV (Shanghai), 202010%30moderatenot evaluable PCR-negative conversion (14-day)detailed resultsChen, 2020 1.42 [0.26; 7.76] 1.42[0.26; 7.76]Chen, 202010%33moderatenot evaluable ICU admissiondetailed resultsAbd-Elsalam, 2020 0.83 [0.35; 1.95] 0.83[0.35; 1.95]Abd-Elsalam, 202010%194moderatenot evaluable cardiac arrestdetailed resultsSOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49] 1.92[0.35; 10.49]SOLIDARITY (WHO study) HCQ, 202010%1,853moderatenot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] ORCHID, 2020 1.26 [0.56; 2.84] RECOVERY, 2020 1.36 [0.98; 1.90] TEACH, 2020 1.16 [0.55; 2.42] 1.29[0.98; 1.69]Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HC-nCoV (Shanghai), 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 202050%5,685moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-27 16:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 657 - roots T: 290